Cardiac amyloidosis: A treatable disease, often overlooked

Circulation

Volumn 124, Issue 9, 2011, Pages 1079-1085

  Falk, Rodney H ^a  

^a HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,3 DIPHOSPHONO 1,2 PROPANODICARBOXYLIC ACID TC 99M; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BORTEZOMIB; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CONTRAST MEDIUM; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; IMMUNOGLOBULIN LAMBDA CHAIN; LENALIDOMIDE; MELPHALAN; PREALBUMIN; SERUM AMYLOID A; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CASE REPORT; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; DISEASE SEVERITY; DRUG MEGADOSE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EXERCISE TOLERANCE; FEMALE; HEART AMYLOIDOSIS; HEART FAILURE; HEART HEMODYNAMICS; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE BIOPSY; HEART PACING; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; IMMUNOHISTOCHEMISTRY; NONHUMAN; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ELECTROPHORESIS;

ADRENERGIC BETA-ANTAGONISTS; AMYLOIDOSIS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BORONIC ACIDS; CALCIUM CHANNEL BLOCKERS; DEXAMETHASONE; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE; HUMANS; MELPHALAN; MIDDLE AGED; MYOCARDIUM; PREALBUMIN; PYRAZINES; SEVERITY OF ILLNESS INDEX; STEM CELL TRANSPLANTATION; THALIDOMIDE; TREATMENT OUTCOME;

EID: 80052286754     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.010447     Document Type: Article

References (22)

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003; 349:583-596. (Pubitemid 36951371)
2. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32:45-59. (Pubitemid 24370135)
3. Kristen AV, Dengler TJ, Hegenbart U, Schonland SO, Goldschmidt H, Sack FU, Voss F, Becker R, Katus HA, Bauer A. Prophylactic implantation of cardioverterdefibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm. 2008;5:235-240.
4. Dubrey SW, Cha K, Anderson J, Chamarthi B, Reisinger J, Skinner M, Falk RH. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998;91:141-157. (Pubitemid 28102667)
5. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, Sheppard MN, Poole-Wilson PA, Hawkins PN, Pennell DJ. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111:186-193. (Pubitemid 40139730)
6. Dubrey SW, Cha K, Skinner M, LaValley M, Falk RH. Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart. 1997;78:74-82. (Pubitemid 27346885)
7. Shi J, Guan J, Jiang B, Brenner DA, Del Monte F, Ward JE, Connors LH, Sawyer DB, Semigran MJ, Macgillivray TE, Seldin DC, Falk R, Liao R. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci USA. 2010;107:4188-4193.
8. Connors LH, Prokaeva T, Lim A, Theberge R, Falk RH, Doros G, Berg A, Costello CE, O'Hara C, Seldin DC, Skinner M. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J. 2009;158:607-614.
9. Buxbaum J, Alexander A, Koziol J, Tagoe C, Fox E, Kitzman D. Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies. Am Heart J. 2010;159:864-870.
10. Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med. 2005;165:1425-1429. (Pubitemid 40973426)
11. Perugini E, Guidalotti PL, Salvi F, Cooke RMT, Pettinato C, Riva L, Leone O, Farsad M, Ciliberti P, Bacchi-Reggiani L, Fallani F, Branzi A, Rapezzi C. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46: 1076-1084. (Pubitemid 41316518)
12. Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, Mangione PP, Gallimore JR, Millar DJ, Minogue S, Dhillon AP, Taylor GW, Bradwell AR, Petrie A, Gillmore JD, Bellotti V, Botto M, Hawkins PN, Pepys MB. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature. 2010;468:93-97.
13. Comenzo RL. How I treat amyloidosis. Blood. 2009;114:3147-3157.
14. Hacihanefioglu A, Tarkun P, Gonullu E. Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int J Hematol. 2008;88:219-222.
15. Dispenzieri A, Dingli D, Kumar SK, Rajkumar SV, Lacy MQ, Hayman S, Buadi F, Zeldenrust S, Leung N, Detweiler-Short K, Lust JA, Russell SJ, Kyle RA, Gertz MA. Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. Am J Hematol. 2010;85: 757-759.
16. Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, Recher C, Asli B, Lioure B, Royer B, Jardin F, Bridoux F, Grosbois B, Jaubert J, Piette JC, Ronco P, Quet F, Cogne M, Fermand JP. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007;357:1083-1093. (Pubitemid 47443213)
17. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, McConnell JP, Litzow MR, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, Hogan WJ, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Snow DS, Hayman SR, McGregor CG, Jaffe AS. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2004;104:1881-1887. (Pubitemid 39202301)
18. Coelho T, Maia L, Martins da Silva A, Waddington Cruz M, Planté-Bordeneuve V, Lozeron P, Suhr OB, Campistol J, Conceic ̧ao I, Schmidt H, Trigo P, Packman J, Grogan DR. A comprehensive evaluation of the disease-modifying effects of tafamidis in patients with transthyretin type familial amyloid polyneuropathy. Presented at: American Academy of Neurology Annual Meeting; April 2011; Honolulu, HI.
19. Kolstoe SE, Mangione PP, Bellotti V, Taylor GW, Tennent GA, Deroo S, Morrison AJ, Cobb AJ, Coyne A, McCammon MG, Warner TD, Mitchell J, Gill R, Smith MD, Ley SV, Robinson CV, Wood SP, Pepys MB. Trapping of palindromic ligands within native transthyretin prevents amyloid formation. Proc Natl Acad Sci USA. 2010;107: 20483-20488.
20. Kurosawa T, Igarashi S, Nishizawa M, Onodera O. Selective silencing of a mutant transthyretin allele by small interfering RNAs. Biochem Biophys Res Commun. 2005;337: 1012-1018. (Pubitemid 41447013)
21. Benson MD, Kluve-Beckerman B, Zeldenrust SR, Siesky AM, Bodenmiller DM, Showalter AD, Sloop KW. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve. 2006;33: 609-618.
22. Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V, Gillmore JD, Palladini G. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol. 2010;28:1031-1037.